
OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal CVC, and Weiss Asset Management
OliX Pharmaceuticals Raises KRW 110 Billion in Strategic Investment from L’Oréal’s BOLD and Weiss Asset Management OliX Pharmaceuticals, Inc., a leading biotechnology company specializing in RNA interference (RNAi) therapeutics, has…












